Search

Displaying results 4901 - 4910 of 10000 in total
  1. Drug

    ORE-1001

    go.drugbank.com/drugs/DB12271
    Investigational

    ORE1001 has been used in trials studying the treatment of Mild to Moderate Ulcerative Colitis. It is an ACE2 inhibitor.

  2. Drug

    Erteberel

    go.drugbank.com/drugs/DB07933
    Investigational

    Erteberel is an estrogen receptor beta agonist that has been used in trials studying the treatment of Benign Prostatic Hyperplasia.

    Synonyms: (3aS,4R,9bR)-4-(4-Hydroxyphenyl)-1,2,3,3a,4,9b-hexahydrocyclopenta(c)(1) benzopyran-8-ol
  3. Drug

    Snail, unspecified

    go.drugbank.com/drugs/DB14245
    ApprovedInvestigational

    Snail, unspecified is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.

  4. Drug

    Inecalcitol

    go.drugbank.com/drugs/DB04796
    Investigational

  5. Drug

    Ferumoxides

    go.drugbank.com/drugs/DB09508
    Approved

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Laropiprant

    go.drugbank.com/drugs/DB11629
    ApprovedWithdrawn

    Laropiprant is an ingredient in the EMA-withdrawn product Pelzont.

  7. Drug

    Scorpion (centruroides) immune Fab2 antivenin (equine)

    go.drugbank.com/drugs/DB13905
    Approved

    It was approved by FDA in 2011 and is marketed under the name Anascorp [L2196]. Anascorp is produced from equine IgG antibodies. … Severe scorpion stings may cause loss of muscle control and respiratory failure, warranting heavy sedation and hospitalization in an intensive care unit.

  8. Drug

    Meningococcal polysaccharide vaccine group W-135

    go.drugbank.com/drugs/DB13887
    ApprovedInvestigational

    It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup W-135. … *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia.

  9. Drug

    Ganulameran

    go.drugbank.com/drugs/DB16442
    Investigational

    As such, BNT162b3 has entered a phase I/II study in early September 2020 (NCT04537949). … Pfizer and BioNTech deemed this compound as promising in preclinical trials and have decided to initiate further testing of it.

  10. Drug

    Denibulin

    go.drugbank.com/drugs/DB05932
    Experimental

    Denibulin is a novel small molecule Vascular Disrupting Agent under development by MediciNova for treatment of solid tumor cancers.